ARWR - Arrowhead Pharmaceuticals asks regulators to begin early-stage asthma trial

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has filed an application with New Zealand authorities seeking permission to begin a phase 1/2 trial of ARO-MUC5AC, its candidate for  asthma and other muco-obstructive pulmonary diseases. ARO-MUC5AC is an RNAi therapeutic that is designed to reduce production of the protein mucin 5AC (MUC5AC). The application was sent to the New Zealand Medicines and Medical Devices Safety Authority for review by the Standing Committee on Therapeutic Trials. Arrowhead (ARWR) plans to enroll up to 42 healthy participants and up to 16 patients with asthma in the trial. The company also announced a pulmonary R&D day on May 26. Read why Seeking Alpha contributor Edmund Ingham views Arrowhead (ARWR) as a hold.

For further details see:

Arrowhead Pharmaceuticals asks regulators to begin early-stage asthma trial